| Autor: |
Kivlighn SD; Department of Cardiovascular Pharmacology, Merck Research Laboratories, West Point, PA 19486, USA., Zingaro GJ, Gabel RA, Broten TP, Chang RS, Ondeyka DL, Mantlo NB, Gibson RE, Greenlee WJ, Siegl PK |
| Jazyk: |
angličtina |
| Zdroj: |
European journal of pharmacology [Eur J Pharmacol] 1995 Dec 29; Vol. 294 (2-3), pp. 439-50. |
| DOI: |
10.1016/0014-2999(95)00564-1 |
| Abstrakt: |
L-163,017 (6-[benzoylamino]-7-methyl-2-propyl-3-[[2'-(N-(3-methyl-1-butoxy) carbonylaminosulfonyl)[1,1']-biphenyl-4-yl]methyl]-3H-imidazo[4,5- b]pyridine) is a potent, orally active, nonpeptide angiotensin II receptor antagonist. Conscious rats and dogs were dosed p.o. and i.v.; in both species the plasma bioequivalents are similar at the angiotensin AT1 and AT2 receptor sites indicating balanced activity is maintained in vivo. L-163,017 prevents the pressor response to intravenous (i.v.) angiotensin II in the conscious rat, dog, and rhesus monkey. L-163,017 also significantly reduces blood pressure in a renin-dependent model of hypertension, similar to an angiotensin converting enzyme inhibitor (Enalapril) and an angiotensin AT1 receptor-selective antagonist (L-159,282). These studies indicate that neither the angiotensin AT2 receptor nor bradykinin is important in the acute antihypertensive activity of angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect